Plasma Long Non-Coding RNA RP11-438N5.3 Level for Non-Small Cell Lung Cancer Diagnosis [Letter]
Chun-Qiu Yang, 1 Guo-Ming Zhang 2
1Department of Laboratory Medicine, Taihe County People’s Hospital, Fuyang 236600, People’s Republic of China; 2Department of Laboratory Medicine, Shuyang People’s Hospital, Shuyang Hospital Affiliated to Xuzhou Medical University, Shuyang 223600, People’s Republic of China
Correspondence: Guo-Ming Zhang
Department of Laboratory Medicine, Shuyang People’s Hospital, The Affiliated Shuyang Hospital of Xuzhou Medical University, Shuyang 223600, People’s Republic of China
Chen et al 1 published an article entitled “Plasma Long Non-Coding RNA RP11-438N5.3 as a Novel Biomarker for Non-Small Cell Lung Cancer” in the Cancer Management and Research journal. To evaluate the diagnostic efficiency of Plasma level of RP11-438N5.3 for non-small-cell lung cancer (NCLC), the investigators enrolled 69 NCLC patients and 69 healthy controls in this study. Plasma level of RP11-438N5.3 was determined using quantitative reverse transcription PCR (qRT-PCR), and receiver operating characteristic (ROC) curve analysis was assessed to determine the diagnostic performance of Plasma level of RP11-438N5.3 level in NCLC. They found that Plasma level of RP11-438N5.3 level was significantly lower in NCLC patients than healthy controls and the area under ROC curve (AUC) is 0.814. Therefore, they concluded that the Plasma level of RP11-438N5.3 was a novel diagnostic biomarker for NCLC.
View the original paper by Chen and colleagues
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]